Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results , with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Aug 12 (Reuters) - Bio-Techne beat Wall Street estimates for fourth-quarter revenue on Wednesday helped by growth in its research and diagnostics businesses. Here are some details: • Bio-Techne is in ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.